重组骨形态发生蛋白-7在肾纤维化治疗中的研究进展  

Progerss in the research of rhBMP-7 in therapy for tubulointerstitial fibrosis

作　　者：迟名锋[1] 王世立[1] 韩金祥[1] 

机构地区：[1]山东省医药生物技术研究中心卫生部生物技术药物重点实验室,济南250062

出　　处：《中国新药杂志》2008年第24期2089-2092,共4页Chinese Journal of New Drugs

基　　金：国家高技术研究发展计划(863)项目(2003AA2Z3532)

摘　　要：骨形态发生蛋白-7是一种多功能细胞因子,与相应受体结合后经信号转导发挥作用,受多种拮抗剂和激动剂的调控。肾间质纤维化是多种肾脏疾病进展到终末期肾衰竭的共同途径和主要病理基础。在多项慢性肾脏疾病动物模型的研究中,发现给予重组骨形态发生蛋白-7能够抑制或逆转肾小管间质纤维化,改善肾功能。骨形态发生蛋白-7可能通过维持肾小管细胞表型、逆转上皮-间质细胞转变、减少细胞外基质、抑制炎症等环节发挥抗纤维化作用。文中就重组骨形态发生蛋白-7在肾纤维化治疗中的研究进展进行综述。Bone morphogenetic protein-7 （BMP-7） is a multifunctional cytokine. BMP-7 functions via sighal transduction which is initiated by ligand binding to special receptors, so its action is modulated by several antagonists and agonists. Tubulointerstitial fibrosis is the common consequence and pathological change of several kidney diseases in the progression to end-stage renal failure. Recent studies have demonstrated that recombinant human bone morphogenetic protein-7 （rhBMP-7） has therapeutic effects in various animal models of chronic renal injury. rhBMP-7 improves renal function by inhibiting, even reversing, tubulointerstitial fibrosis. BMP-7 works in tubular fibrosis therapies by a few proposed mechanisms： maintaining the phenotype of tubular epithelial cell structures ; reversing epithelial-mesenchymal transition ; decreasing extracellular matrix ; inhibiting the release of inflammatory factors. The advances in rhBM-7 for tubulointerstitial therapy were reviewed in this paper.

关 键 词：骨形态发生蛋白-7(BMP-7) 慢性肾病 肾间质纤维化 

分 类 号：R692[医药卫生—泌尿科学]